Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change
Top Cited Papers
- 4 August 2009
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 151 (3) , 206-209
- https://doi.org/10.7326/0003-4819-151-3-200908040-00126
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Comparative Effectiveness Research: A Report From the Institute of MedicineAnnals of Internal Medicine, 2009
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant ChemotherapyClinical Pharmacology & Therapeutics, 2009
- Explanatory and Pragmatic Attitudes in Therapeutical TrialsJournal of Clinical Epidemiology, 2009
- Improving the reporting of pragmatic trials: an extension of the CONSORT statementBMJ, 2008
- Assessing the Impact of Protocol Design Changes on Clinical Trial PerformanceClinical Journal of Sport Medicine, 2008
- Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of Cancer and Leukemia Group BJournal of Clinical Oncology, 2006
- Reducing the costs of phase III cardiovascular clinical trialsAmerican Heart Journal, 2005
- Adaptive Randomized Study of Idarubicin and Cytarabine Versus Troxacitabine and Cytarabine Versus Troxacitabine and Idarubicin in Untreated Patients 50 Years or Older With Adverse Karyotype Acute Myeloid LeukemiaJournal of Clinical Oncology, 2003
- Seamlessly Expanding a Randomized Phase II Trial to Phase IIIBiometrics, 2002
- Statistical analysis and the illusion of objectivity: Berger JO, Berry OA: Am Sci 76:159–165, 1988Infectious Diseases Newsletter, 1988